NewLink Genetics Corp (NASDAQ:NLNK) was upgraded by equities research analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a report issued on Thursday.

Other equities research analysts have also recently issued research reports about the company. Zacks Investment Research raised NewLink Genetics Corp from a “hold” rating to a “buy” rating and set a $12.00 target price for the company in a research note on Wednesday, June 7th. Cantor Fitzgerald set a $32.00 target price on NewLink Genetics Corp and gave the stock a “buy” rating in a research note on Sunday, June 4th. Jefferies Group LLC reissued a “hold” rating and set a $7.00 target price on shares of NewLink Genetics Corp in a research note on Friday, July 14th. Finally, Robert W. Baird cut NewLink Genetics Corp from an “outperform” rating to a “neutral” rating and cut their target price for the stock from $25.00 to $8.00 in a research note on Thursday, June 8th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and three have given a buy rating to the company. NewLink Genetics Corp presently has an average rating of “Hold” and an average price target of $18.17.

Shares of NewLink Genetics Corp (NASDAQ:NLNK) traded up 74.58% during trading on Thursday, hitting $13.60. The stock had a trading volume of 28,847,710 shares. The firm’s 50-day moving average is $7.21 and its 200 day moving average is $12.81. NewLink Genetics Corp has a 52-week low of $5.90 and a 52-week high of $25.17. The firm’s market cap is $400.13 million.

NewLink Genetics Corp (NASDAQ:NLNK) last posted its earnings results on Friday, July 28th. The biotechnology company reported ($0.57) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.78) by $0.21. The company had revenue of $10.37 million during the quarter, compared to analysts’ expectations of $2.65 million. NewLink Genetics Corp had a negative return on equity of 61.84% and a negative net margin of 161.29%. On average, analysts expect that NewLink Genetics Corp will post ($2.82) EPS for the current year.

COPYRIGHT VIOLATION WARNING: This story was originally posted by American Banking News and is owned by of American Banking News. If you are viewing this story on another domain, it was stolen and republished in violation of US and international trademark and copyright law. The original version of this story can be accessed at https://www.americanbankingnews.com/2017/09/07/newlink-genetics-corp-nlnk-upgraded-by-valuengine-to-sell.html.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Wells Fargo & Company MN boosted its position in shares of NewLink Genetics Corp by 3.0% during the first quarter. Wells Fargo & Company MN now owns 162,926 shares of the biotechnology company’s stock worth $3,926,000 after buying an additional 4,701 shares during the period. Driehaus Capital Management LLC purchased a new position in shares of NewLink Genetics Corp during the first quarter worth $5,127,000. Northwest Wealth Management LLC boosted its position in shares of NewLink Genetics Corp by 3.1% during the second quarter. Northwest Wealth Management LLC now owns 58,022 shares of the biotechnology company’s stock worth $426,000 after buying an additional 1,740 shares during the period. Teachers Advisors LLC boosted its position in shares of NewLink Genetics Corp by 2.8% during the fourth quarter. Teachers Advisors LLC now owns 201,807 shares of the biotechnology company’s stock worth $2,075,000 after buying an additional 5,500 shares during the period. Finally, Prudential Financial Inc. purchased a new position in shares of NewLink Genetics Corp during the first quarter worth $443,000. Institutional investors and hedge funds own 54.78% of the company’s stock.

NewLink Genetics Corp Company Profile

NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for NewLink Genetics Corp (NASDAQ:NLNK)

Receive News & Ratings for NewLink Genetics Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics Corp and related companies with MarketBeat.com's FREE daily email newsletter.